Therapeutic equivalence: All studies are not created equal

Canadian Journal of Clinical Pharmacology

Volumn 6, Issue 1, 1999, Pages 9-11

  Hatala, Rose ^a,c   Holbrook, Anne ^a,b   Goldsmith, Charles H ^a,b  

^a MCMASTER UNIVERSITY   (Canada)

^b ST JOSEPH S HOSPITAL   (Canada)

^c HENDERSON GENERAL HOSPITAL   (Canada)

Author keywords

Equivalence trials; Minimally important difference; Therapeutic options

Indexed keywords

COST BENEFIT ANALYSIS; DRUG EFFICACY; DRUG RESEARCH; DRUG SAFETY; METHODOLOGY; SHORT SURVEY;

EID: 0032923210     PISSN: 1198581X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Short Survey

References (9)

1. Garbe E, Rohmel J, Gundert-Remy U. Clinical and statistical issues in therapeutic equivalence trials. Eur J Clin Pharmacol 1993;455:l-7.
2. Redelmeire DA, Guyatt GH, Goldstein RS. Assessing the minimal important difference in symptoms: a comparison of two techniques. J Clin Epidemiol 1996;49:1215-9.
3. Naylor CD, Llewellyn-Thomas HA. Can there be a more patient-centred approach to determining clinically important effect sizes for randomized treatment trials? J Clin Epidemiol 1994;47:787-95.
4. Bratt G, Aberg W, Johansson M, Tornebohm E, Granqvist S, Lockner D. Two daily subcutaneous injections of fragmin as compared with intravenous standard heparin in the treatment of deep venous thrombosis (DVT). Thromb Haemost 1990;64:506-10.
5. Guyatt GH, Sackett DL, Cook DJ. Users' guides to the medical literature. II. How to use an article about therapy or prevention. A. Are the results of the study valid? Evidence-Based Medicine Working Group. JAMA 1993;270:2598-601.
6. Koopman MMW, Prandoni P, Piovella F, et al. Treatment of venous thrombosis with intravenous unfractionated heparin administered in the hospital as compared with subcutaneous low-molecular-weight heparin administered at home. N Engl J Med 1996;334:682-7.
7. Kirshner B. Methodological standards for assessing therapeutic equivalence. J Clin Epidemiol 1991;44:839-49.
8. Jones B, Jarvis P, Lewis JA, Ebbutt AF. Trials to assess equivalence: the importance of rigorous methods. BMJ 1996;313:36-9.
9. Hirsh J, Raschke R, Warkentin TE, Dalen JE, Deykin D, Poller L. Heparin: mechanism of action, pharmacokinetics, dosing considerations, monitoring, efficacy, and safety, Chest 1995;108:258S-75S.